CSCO BC Guideline Highlights | Professor Man Li: Focusing on HER2-Low and HER2-Ultralow Breast Cancer — Key Updates and Practical Changes in the 2026 Guidelines

CSCO BC Guideline Highlights | Professor Man Li: Focusing on HER2-Low and HER2-Ultralow Breast Cancer — Key Updates and Practical Changes in the 2026 Guidelines

The 2026 National Breast Cancer Conference was successfully held in Beijing from April 10–12, during which the 2026 Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines were officially released. Oncology Frontier invited Professor Man Li from the Second Affiliated Hospital of Dalian Medical University to discuss three key clinical topics surrounding HER2-low and HER2-ultralow breast cancer: major updates in the 2026 guidelines, standardized interpretation of HER2-low/ultralow status, and sequencing strategies for antibody-drug conjugates (ADCs). Her insights provide more precise and practice-oriented guidance for the management of HER2-low and HER2-ultralow breast cancer in China.
CSCO BC Guideline Highlights | Professor Shusen Wang: Key Updates in Advanced Triple-Negative Breast Cancer Management — From Salvage Chemotherapy to a New Era of Immunotherapy-Based Combination Strategies

CSCO BC Guideline Highlights | Professor Shusen Wang: Key Updates in Advanced Triple-Negative Breast Cancer Management — From Salvage Chemotherapy to a New Era of Immunotherapy-Based Combination Strategies

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) underwent a major update. At the meeting, Professor Shusen Wang from Sun Yat-sen University Cancer Center presented the latest revisions related to the management of advanced triple-negative breast cancer (TNBC).
Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results

Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results

On February 6, 2026, Nature Communications published online a study led by Academician Xu Binghe from the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences. The single-arm Phase Ib trial evaluated the efficacy and safety of the novel oral pan-AKT inhibitor afuresertib combined with fulvestrant in previously treated patients with HR-positive/HER2-negative advanced breast cancer.
A Decade of Pursuing Light, A Future Full of Hope: Tracing the Milestones and Defining Moments of CSCO BC

A Decade of Pursuing Light, A Future Full of Hope: Tracing the Milestones and Defining Moments of CSCO BC

In April 2016, a pink seed took root in Beijing with the launch of preparations for the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC). Driven by vision, dedication, and perseverance, a group of Chinese physicians came together to support and empower patients with breast cancer through science, compassion, and unwavering commitment to care.
Sino-French Breast Reconstruction Congress | Professor Hongyuan Li: Building a Bridge for Sino-French Collaboration and Advancing Breast Reconstruction Accessibility and De-escalation Strategies in Oncoplastic Surgery Through the “Chongqing Experience”

Sino-French Breast Reconstruction Congress | Professor Hongyuan Li: Building a Bridge for Sino-French Collaboration and Advancing Breast Reconstruction Accessibility and De-escalation Strategies in Oncoplastic Surgery Through the “Chongqing Experience”

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing, China. During the meeting, Oncology Frontier conducted an exclusive interview with Professor Hongyuan Li from the First Affiliated Hospital of Chongqing Medical University (hereafter referred to as CQMU First Hospital), one of the conference’s principal organizers. In the interview, Professor Li shared his insights into the innovative considerations behind this year’s conference design, the reproducible experience of CQMU First Hospital in promoting technical standardization and multidisciplinary talent development, as well as the institution’s “Chongqing Experience” in individualized oncoplastic breast surgery and de-escalation treatment strategies.
Sino-French Breast Reconstruction Congress | Professor Shengchun Liu: Pursuing Maximum Benefit with Minimal Invasiveness — Individualized Breast Reconstruction Practice and Insights for Chinese Women

Sino-French Breast Reconstruction Congress | Professor Shengchun Liu: Pursuing Maximum Benefit with Minimal Invasiveness — Individualized Breast Reconstruction Practice and Insights for Chinese Women

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing, China. During the meeting, Professor Shengchun Liu from the First Affiliated Hospital of Chongqing Medical University sat down with Oncology Frontier to share the “CQMU experience” accumulated over more than two decades. In the interview, Professor Liu discussed the evolution of breast reconstruction strategies from an early predominance of autologous flap reconstruction to the current implant-oriented approach, and explained how breast surgeons should continue to uphold the principle of “achieving optimal outcomes with the least possible surgical trauma” amid the growing trends of minimally invasive surgery and artificial intelligence.
The World Needs Me, and I Need the World — Professor Kefeng Ding: Chinese and International Experts Discuss Key Colorectal Surgical Techniques as ICSTAC Builds New Pathways for Global Surgical Training

The World Needs Me, and I Need the World — Professor Kefeng Ding: Chinese and International Experts Discuss Key Colorectal Surgical Techniques as ICSTAC Builds New Pathways for Global Surgical Training

On April 24, 2026, the China–Spain–Canada Colorectal Surgery Clinical Practice Symposium was successfully held at the Chengdong Campus of the Second Affiliated Hospital, Zhejiang University School of Medicine. Renowned surgical experts and scholars from China, Spain, and Canada gathered to engage in in-depth academic exchanges focused on live surgical demonstrations, operative technique sharing, and presentations of cutting-edge technologies.
CUDA Yanqi Lake Conference | Professor Ninghan Feng: Multidisciplinary Integration Empowering the Management of Complex Urologic Tumors — The Practice and Future of the MDT Model

CUDA Yanqi Lake Conference | Professor Ninghan Feng: Multidisciplinary Integration Empowering the Management of Complex Urologic Tumors — The Practice and Future of the MDT Model

As oncology treatment paradigms continue to evolve, the multidisciplinary team (MDT) approach has become a cornerstone of modern cancer care, particularly for the management of complex malignancies. In the field of urologic oncology, MDT care integrates expertise from surgery, medical oncology, radiation oncology, imaging, pathology, and other specialties to provide individualized, full-spectrum treatment strategies that significantly improve patient outcomes.
CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?

CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?

Prostate cancer is the second most commonly diagnosed malignancy and the fifth leading cause of cancer-related death among men worldwide. In recent years, with the rapid advancement of molecular biology technologies and the emergence of novel therapeutic agents, prostate cancer management has officially entered the era of precision medicine. Clinical decision-making is undergoing a profound transformation—from the traditional “one-size-fits-all” approach to individualized treatment strategies guided by precise staging and molecular profiling.
CUDA Yanqi Lake Conference | From Personal Mastery to Broader Impact: The Growth and Legacy of a Urologic Surgeon

CUDA Yanqi Lake Conference | From Personal Mastery to Broader Impact: The Growth and Legacy of a Urologic Surgeon

The 2026 Yanqi Lake Academic Conference for Urologists was successfully held in Beijing. During the meeting, Conference Chair Professor Nianzeng Xing, Vice President of the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences, shared his personal journey during the special session “From a Skilled Commander to a Strategic Leader.” He reflected on his transformation from a surgeon striving for technical perfection in the operating room to a discipline leader committed to cultivating teams and advancing the field as a whole.